FINANCIAL TRUST COMPANY INC ACCT. For the Period 7/1/12 to 7/31/12 Note P indicates position adjusted for Pending Trade Activity. Unrealized GainiLoss is shown as "N A" in cases where we do not have appropriate cost information for all lax lots comprising the position. Please contact your J P Morgan team for additional information. Equity Detail Price Quality Value Adjusted Tax Cost Unrealized Est. Annual Inc. Original Cost Gain/Loss Accrued Div. Yield US Large Cap Equity ARIAD PHARMACEUTICALS INC 19.13 16,535.000 316,314.55 251,475.52 64,839.03 04033A-10-0 ARIA BIOGEN IDEC INC 145.83 2.095 000 305,513.85 250,454.95 55,058.90 09062X-10-3 BIIB DB CONT BUFF EQ MS 08/07/12 64.77 1.000.000 000 847.880.00 1,000,000.00 (352,340.00) 25% CONTIN BARRIER- 13%CPN 30% CAP INITIAL LEVEL-07,1511 MS 21 09 2515A1-A7-6 FACEBOOK ■4C-A 21.71 35,000.000 759,850.00 1,330,000.00 (570,150.00) 30303M-10-2 FB GS CONT BUFF EQ SPX 7/9/13 101.74 3,000,000.000 3,052,140.00 3,000,000.00 52,140.00 80% CONTIN BARRIER- 10.5%CPN 15% CAP INITIAL LEVEL-8/20/12 SPX:1355.89 38143U-7.9-6 HSBC MARKET PLUS SPX 06/7/13 100.71 5,000,000.000 5,035,500.00 5,000,000.00 36,500.00 72% KO BARRIER- 0%CPN ,UNCAPPED INITIAL LEVEL-02/14/12 SPX:1350.50 4042K1-X0-1 JP Morgan Account Page 5 of 28 Consolidated Statement Page 8 Confidential Treatment Requested by JPMorgan Chase CONFIDENTIAL JPM-SDNY-00016112 SDNY_GM_00285310 EFTA01493268